NuwellisNUWE
NUWE
About: Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
Employees: 38
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
57% more funds holding
Funds holding: 7 [Q4 2024] → 11 (+4) [Q1 2025]
40% more capital invested
Capital invested by funds: $91.5K [Q4 2024] → $129K (+$37.1K) [Q1 2025]
1.28% more ownership
Funds ownership: 1.89% [Q4 2024] → 3.16% (+1.28%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for NUWE.
Financial journalist opinion
Neutral
GlobeNewsWire
4 days ago
Nuwellis Announces Closing of $5.0 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
MINNEAPOLIS, June 10, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the closing of a public offering of 2,580,667 shares of its common stock (“Common Stock”), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 49,999,995 shares of Common Stock and Series B Warrants to purchase up to 16,666,665 shares of Common Stock with gross proceeds of approximately $5.0 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants.
Neutral
GlobeNewsWire
6 days ago
Nuwellis Announces Pricing of $4.3 Million Underwritten Public Offering
MINNEAPOLIS, June 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the pricing of a public offering of 406,755 shares of its common stock (“Common Stock”), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 43,478,259 shares of Common Stock and Series B Warrants to purchase up to 14,492,753 shares of Common Stock.
Neutral
Seeking Alpha
1 month ago
Nuwellis, Inc. (NUWE) Q1 2025 Earnings Call Transcript
Nuwellis, Inc. (NASDAQ:NUWE ) Q1 2025 Earnings Conference Call May 13, 2025 9:00 AM ET Company Participants Louisa Smith - IR, Gilmartin Group John Erb - Chairman & Interim CEO Rob Scott - CFO Conference Call Participants Jonathan Aschoff - ROTH Operator Good day, everyone, and welcome to Nuwellis First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
1 month ago
Nuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates
Nuwellis, Inc. (NUWE) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $20.98 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.
Neutral
GlobeNewsWire
1 month ago
Nuwellis Contracts with KDI Precision Manufacturing to Strengthen Production and Improve Operational Efficiency
Strategic agreement is expected to reduce costs, preserve expertise, and streamline operations. WHO WHAT WHERE WHEN WHY Nuwellis, Inc. (Nasdaq: NUWE) and KDI Precision Manufacturing Outsourcing manufacturing and assembly of key Aquadex product components.
Neutral
GlobeNewsWire
1 month ago
Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems
MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced a meaningful step forward for children facing fluid overload with the recent expansion of its Aquadex SmartFlow® therapy into two additional pediatric centers across the Southeastern United States. The company now has 47 pediatric centers that have adopted Aquadex therapy as part of their fluid management approach.
Neutral
GlobeNewsWire
1 month ago
Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves Precision
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced the issuance of U.S. Patent No. 12,280,007 by the U.S. Patent and Trademark Office. The newly granted patent covers a fluid bag design that passively drains once full—reducing the need for manual intervention by clinical staff while preserving the system's precise weight-based measurement.
Neutral
GlobeNewsWire
1 month ago
Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025
MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.
Neutral
Seeking Alpha
3 months ago
Nuwellis, Inc. (NUWE) Q4 2024 Earnings Call Transcript
Nuwellis, Inc. (NASDAQ:NUWE ) Q4 2024 Earnings Conference Call March 11, 2025 9:00 AM ET Company Participants Vivian Cervantes - Gilmartin Group, Investor Relations John Erb - Interim President and Chief Executive Officer Rob Scott - Chief Financial Officer Conference Call Participants Jonathan Aschoff - Roth Anthony Vendetti - Maxim Group Operator Good morning. And welcome to Nuwellis Earnings Conference Call for the Fourth Quarter and Full Year ended December 31, 2024.
Charts implemented using Lightweight Charts™